Windhover's Pharma Business Strategies for Biomarkers

Apr. 9, 2009
Webinar
www.windhover.com/ezine/html/Biomarkers_Series_3.htm

Description:

Cancer Biomarkers: Case Studies in Lessons Learned and Experiments in Process

Ben Bonifant, Vice President and head of the Business Development Practice at Campbell Alliance, discusses the importance of oncology biomarkers in making BD and commercial decisions.

Abstract:

Cancer Biomarkers: Case Studies in Lessons Learned and Experiments in Process

There's no question biomarkers play a critical role in the drug development process, both in the clinical trial design and positioning a medicine in the marketplace. In most therapeutic areas, however, the science behind biomarkers is still at a nascent stage. The one exception? Oncology, where well validated markers have played--and continue to play--a key role in the success of important therapeutics such as Herceptin, Erbitux, and Vectibix. In this webinar, we'll hear from experts about the importance of biomarkers in the development of AstraZeneca's Iressa and Amgen's Vectibix, as well as from other stakeholders about what our evolving knowledge of oncology biomarkers means for the cancer medicines of tomorrow.

Moderators:

Roger Longman, Managing Director, Windhover Information

Ellen Licking, Executive Editor, Windhover Information

Panelists:

Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance

Ruth March,
Personalized Healthcare Director, AstraZeneca

David Chang,
M.D., Ph.D., Vice President, Global Development, Amgen

Spiro Rombotis, President & CEO, Cyclacel Pharmaceuticals 

View Entire Event Calendar

Don't Miss